CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Thirty-two male DSM-III diagnosed schizophrenic patients received a lumbar puncture (LP) during chronic haloperidol treatment that was followed by replacement with placebo for up to 6 weeks. Fourteen patients relapsed on placebo within 6 weeks. Patients received a second LP at the time of relapse or at the end of 6 weeks if they had not relapsed. Bunney-Hamburg Global Psychosis Ratings of the day and the hours of sleep of the night before the LP were obtained, as were the Brief Psychiatric Ratings Scale (BPRS) ratings during the week of the LPs. CSF norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5 HIAA) concentrations were measured with high-pressure liquid chromatography (HPLC). Patients who relapsed had significantly higher CSF NE levels on and off haloperidol than patients who did not relapse. CSF MHPG was higher in the relapsers in the drug-free condition only, but CSF HVA and 5-HIAA were not significantly different in either condition. In the drug-free relapsed patients, CSF NE correlated significantly with the psychosis ratings of the day and hours of sleep the night prior to the LP. Our data indicate that elevated CSF NE levels during neuroleptic treatment may predict behavioral decompensation after discontinuing the medication.
van Kammen
D P
DP
Veterans Administration Medical Center, Pittsburgh, PA 15206.
Peters
J
J
van Kammen
W B
WB
Nugent
A
A
Goetz
K L
KL
Yao
J
J
Linnoila
M
M
D000328:Adult; D002851:Chromatography, High Pressure Liquid; D002908:Chronic Disease; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D009638:Norepinephrine / Q000134:cerebrospinal fluid*; D011569:Psychiatric Status Rating Scales; D012008:Recurrence; D012307:Risk Factors; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D013375:Substance Withdrawal Syndrome / Q000134:cerebrospinal fluid*
D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D006220:Haloperidol; D009638:Norepinephrine; D006719:Homovanillic Acid